Every 10-Q that vTv Therapeutics Inc. (VTVT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow VTVT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VTVT filings page.
vTv Therapeutics Inc. reported $36.8 million in collaboration and license revenue for the six months ended June 30, 2026, driven by a $20.0 million upfront payment from Newsoara and $16.9 million of license revenue recognized upon lifting IP restrictions for its G42 collaboration. This produced operating income of $9.3 million and net income of $11.1 million, compared with a loss a year earlier, although the company still carries an accumulated deficit of $315.6 million.
Research and development spending rose sharply to $17.7 million in the first half, largely to advance cadisegliatin, its Phase 3 oral adjunctive therapy for type 1 diabetes, and supporting studies. Cash and cash equivalents were $86.6 million at June 30, 2026, with net cash used in operating activities of $2.3 million. Management states it expects continued operating losses tied to ongoing trials and anticipates needing substantial additional capital over time despite the recent non-recurring license inflows.
vTv Therapeutics reported a sharp turnaround in the quarter ended March 31, 2026, driven by licensing revenue. Revenue reached $36.8 million, all from collaboration and license agreements, primarily a $20.0 million upfront payment and additional milestone and license revenue from Newsoara and G42.
Research and development expenses rose to $9.0 million from $2.8 million as the company advanced its lead Type 1 diabetes candidate cadisegliatin and other projects. General and administrative costs increased to $4.6 million. vTv generated net income of $24.1 million, compared with a $6.2 million loss a year earlier.
Cash and cash equivalents grew to $98.1 million from $88.9 million at year-end 2025, helped by the Newsoara payment and recognition of deferred G42 license consideration, giving the company more flexibility to fund ongoing Phase 3 and supporting trials for cadisegliatin and other pipeline work.
vTv Therapeutics Inc. reported Q3 2025 results. The company recorded no revenue, with operating expenses of $10.7 million (research and development $7.0 million; general and administrative $3.7 million), leading to a net loss attributable to vTv of $8.7 million and basic/diluted loss per share of $1.08.
Liquidity improved, with cash and cash equivalents $98.5 million at September 30, 2025, supported by an August private placement that brought aggregate gross proceeds of approximately $80.0 million (net financing cash inflow $77.8 million). Management now indicates there is no longer substantial doubt about the company’s ability to continue as a going concern for at least twelve months from issuance.
Development advanced: the FDA removed the cadisegliatin clinical hold on March 14, 2025, and the CATT1 Phase 3 protocol was shortened to six months; top‑line data are expected in the second half of 2026. Shares outstanding were 3,938,018 Class A and 241 Class B as of November 6, 2025.
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on oral small-molecule therapies for diabetes, led by cadisegliatin, a potential first-in-class liver-selective glucokinase activator in a Phase 3 trial. The FDA removed a clinical hold on the cadisegliatin program on March 14, 2025, the company reinitiated patient screening in May 2025, randomized the first participant on August 6, 2025, and shortened the CATT1 study from 12 to 6 months; top-line data are expected in the second half of 2026. The U.S. Patent Office allowed claims for a crystalline salt form of cadisegliatin in August 2025.
On the balance sheet as of June 30, 2025, vTv held $25.9 million in cash, had an accumulated deficit of $310.9 million, and reported a six-month net loss attributable to common shareholders of $11.1 million. There was no product revenue in H1 2025 (prior period included $1.0 million of collaboration revenue in H1 2024). The company completed a $51.0 million private placement in February 2024 and has an ATM program; however, management discloses substantial doubt about the company’s ability to continue as a going concern without additional financing.